Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TransCon TLR7/8 Agonist |
Trade Name | |
Synonyms | Resiquimod Hydrogel-based Sustained-release formulation |
Drug Descriptions |
TransCon TLR7/8 Agonist is a hydrogel based formulation of an imidazoquinolinamine and resiquimod, which acts as an agonist of TLR 7 and TLR8, which potentially activates the antitumor immune response and may lead to tumor cell lysis (NCI Drug Dictionary). |
DrugClasses | TLR7 Agonist 12 TLR8 Agonist 9 |
CAS Registry Number | NA |
NCIT ID | C179719 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Pembrolizumab + TransCon TLR7/8 Agonist | Pembrolizumab TransCon TLR7/8 Agonist | 0 | 2 |
TransCon IL-2 beta/gamma + TransCon TLR7/8 Agonist | TransCon IL-2 beta/gamma TransCon TLR7/8 Agonist | 0 | 1 |
TransCon TLR7/8 Agonist | TransCon TLR7/8 Agonist | 0 | 1 |